期刊文献+

G-蛋白偶联受体GPR120分子模建研究 被引量:4

G-Protein-Coupled Receptor 120-GPR120:Molecular Modeling Studies
原文传递
导出
摘要 新的长链脂肪酸受体G-蛋白偶联受体120(G-protein-coupled receptor120,GPR120)是2型糖尿病的潜在治疗靶标.由于其晶体结构迄今尚未获得,成为基于结构的新药设计的瓶颈.首先,以人体β2肾上腺能素受体(human β2 adrenergic receptor,β2AR)晶体结构为模板,通过同源模建方法构建GPR120三维结构,对整个体系进行包膜的分子动力学模拟.然后采用分子对接技术模建了GPR120的小分子激动剂GW9508与GPR120的相互作用模型,发现了受体分子识别的关键性残基,为开展定点突变实验提供了指导意义.所建模型为研究受体与配体作用提供了合理的初始结构,此方法也适用于其他G蛋白偶联受体的分子模建. G-protein-coupled receptor 120 (GPR 120), which functions as a new receptor for long chain free fatty acids, may play a role as a potential therapeutic target for type 2 diabetes mellitus. The three-dimensional (3D) structure of GPR120 is experimentally unavailable to date, however, leading to difficulty in the structure-based drug design. Based on the X-ray crystal structure of f12 adrenergic receptor, a homology model of the GPR120 was constructed, then, molecular-dynamics (MD) simulations were carried out for the entire system. The GPR120 ligand agonist GW9508 was docked into the optimized model, and the critical amino acid residues for binding were identified, which was very important for further site-directed mutagenesis study. The constructed models should provide a good starting point for further characterization of the binding models for GPR120 ligands. Furthermore, the method developed herein will be applicable to build other GPCRs.
出处 《化学学报》 SCIE CAS CSCD 北大核心 2009年第14期1553-1558,共6页 Acta Chimica Sinica
基金 国家863项目(No.2007AA02Z301) 国家自然科学基金(No.20803063)资助项目
关键词 G-蛋白偶联受体 GPR120 同源模建 分子动力学模拟 2型糖尿病 G-protein-coupled receptor (GPCR) GPR120 homology modeling molecular dynamics simulation type 2 diabetes mellitus
  • 相关文献

参考文献36

  • 1Takeda, S.; Ksdowaki, S.; Haga, T.; Takaesu, H.; Mitaku, S. FEBS Lett. 2002, 520, 97.
  • 2Fredriksson, M.; Lagerstrom, M. C.; Lundin, L. G.; Schioth, H. B. Mol. Pharmacol. 2003, 63, 1256.
  • 3Pierce, K. L.; Premont, R. T.; Lefkowitz, R. J. Nat. Rev. Mol. Cell Biol. 2002, 3, 639.
  • 4Lefkowitz, R. J.; Shenoy, S, K. Science 2005, 308, 512.
  • 5Hirasawa, A.; Tsumaya, K.; Awaji, T.; Katsuma, S.; Adachi, T.; Yamada, M.; Sugimoto, Y.; Miyazaki, S.; Tsujimoto, G. Nat Med. 2005, 11, 90.
  • 6卢伊娜,胡慧,朱维良,王贺瑶.GPR120的研究进展[J].生命科学,2008,20(2):275-278. 被引量:8
  • 7Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshirna, H.; Fox, B. A.; Trong, I. L.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Science 2000, 289, 739.
  • 8Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G. F.; Thian, F. S.; Kobilka, T. S.; Choi, H.-J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. Science 2007, 318, 1258.
  • 9Rosenbaum, D. M.; Cherezov, V.; Hanson, M. A.; Rasmussen, S. G. F.; Thian, F. S.; Kobilka, T. S.; Choi, H.-J.; Yao, X.-J.; Weis, W. I.; Stevens, R. C.; Kobilka, B. K. Science 2007, 318, 1266.
  • 10Jaakola, V.-P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.; Chien, E. Y. T.; Lane, J. R.; Ijzerman, A. P.; Stevens, R. C. Science 2008, 322, 1211.

二级参考文献32

  • 1张瑞,谢欣,王明伟.游离脂肪酸受体的结构、分布及功能[J].生命的化学,2005,25(2):92-94. 被引量:2
  • 2龚珍,贺凌燕,柳红,刘景根,朱维良,陈凯先,蒋华良.一个潜在的糖尿病新靶标——GPR40[J].生命科学,2006,18(5):467-472. 被引量:4
  • 3Norbury, C.; Nurse, P. Annu. Rev. Biochem. 1992, 61,441.
  • 4De azevedo, W. F. Jr.; Mueller-Dieckmann, H. J., Schulze-Gahrnen, U.; Worland, P. J.; Sausville, E.; Kim, S.-H. Proc.Natl. Acad. Sci. U. S. A. 1996, 93(7), 2735.
  • 5Hunter, T.; Pines, J. Cell 1994, 79, 573.
  • 6Hoessel, R.; Leclerc, S.; Endicott, J. A.; Nobel, M. E.; Lawde, A.; Tunnah, P.; Leost, M.; Damiens, E.; Marie, D.;Marko, D.; Niederberger, E.; Tang, W.; Eisenbrand, G.;Meiier, L. Nat. Cell Biol. 1999, 1(1), 60.
  • 7Kroemer, R. T.; Doughty, S. W.; Robinson, A. J., Richards,W. G. Protein Eng. 1996, 9(6), 493.
  • 8DS Modeling Version 1.0 User Manual, Acc.elrys Inc., San Diego, 2003.
  • 9Morris, G. M.; Goodsell, D. S.; Huey, R.; Hart, W. E.; Halliday, S.; Belew, R.; Olson, A. J. Autodock Version 3. 05 User Manual, La Jolla, 20011.
  • 10Sybyl Version 6.8 User Manual, Tripos Inc., St. Louis,1999.

共引文献13

同被引文献27

  • 1汪小涧,杨倩,尤启冬.基于分子片段的药物发现[J].中国药科大学学报,2009,40(4):289-296. 被引量:2
  • 2崔永梅,南发俊.生物电子等排原理在药物先导化合物优化中的应用[J].生命科学,2006,18(2):161-167. 被引量:12
  • 3林晓燕,宋和平,胡赟宏.去甲斑蝥素对人乳腺癌血管生成的抑制作用[J].中国癌症杂志,2007,17(11):847-850. 被引量:26
  • 4Ahschulr, Hoffera, Stephen J D. Influence of nicotinic acid on serum cholesterol in man [ J ]. Arch Biochem Biophys, 1955,54 (2) :558.
  • 5Sogat, Kamoharam, Takasakij, et al. Molecular identification of nicotinic acid receptor [ J ]. Biochem Biophys Res Commun, 2003,303( 1 ) :364.
  • 6Carlsonla. Studies on the effect of nicotinic acid on catecholaminestimulated lipolysis in adipose tissue in vitro [ J ]. Acta reed scand, 1963,173(6) :719.
  • 7Patani G A, LaVoie E J. Bioisosterism: a rational approach in- drug design[J]. Chem Rev, 1996, 96(8) : 3147.
  • 8Takigawa, Ichigaku, Tsuda, et al. Mining significant substruc- ture pairs for interpreting polypharmaeology in Drug-Target Net- work[J]. PLoS ONE,2011,2(6) :3.
  • 9Deng Q, Frie J L, Marley D M, et al. Molecular modeling aided design of nicotinic acid receptor GPR109A agonists [ J ]. Bioorg Med Chem Lett, 2008,18 ( 18 ) :4963.
  • 10袁列江,李忠海,郑锦星.槟榔提取物对大白鼠血脂调节作用的研究[J].食品科技,2009,34(2):188-192. 被引量:11

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部